FACTT for Hereditary Breast and Ovarian Cancer

Recruiting in Palo Alto (17 mi)

Overseen byAndrea Hagemann, M.D., MSCI

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Washington University School of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to learn how cancer care providers can help their patients communicate the need for genetic testing in families with inherited cancer syndromes.

Research Team

Andrea Hagemann, M.D., MSCI

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults over 18 with certain inherited cancer syndromes (like Hereditary Breast and Ovarian Cancer or Lynch Syndrome) who've had specific cancers. They must have a mutation known to cause these conditions, be in good general health, mentally able to participate, and willing to do follow-up surveys for up to 6 months.

Inclusion Criteria

I am over 18 years old.

I am mentally and physically able to follow the study's requirements.

I have a confirmed genetic mutation linked to cancer.

See 3 more

Exclusion Criteria

My genetic test shows a variant that is not clearly harmful.

Treatment Details

Interventions

Families Accelerating Cascade Testing Toolkit (Behavioural Intervention)

Trial OverviewThe study tests the Families Accelerating Cascade Testing Toolkit designed to help patients communicate about genetic testing needs within families at risk of hereditary cancers. It aims to understand how providers can support this process.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: FACT Toolkit (FACTT)Experimental Treatment1 Intervention

* Proband: Introduced to FACTT and will complete Cascade Genetic Testing survey. The survey will contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. The probands will also fill out assessments of each FACTT component. At 6 months, there will be a follow-up survey. * Family Member: Introduced to FACTT and will complete surveys at study entry and 6 month follow-up. They will also fill out assessments of each FACTT component

Group II: Usual CareActive Control1 Intervention

* For approximately the first 6 months of the study, or until 75 patient with cancer who is initially approached in clinic (probands) are enrolled, the investigators will be enrolling probands into the "Usual Care" group. During this time, the investigators will clarify usual care regarding cascade genetic testing for each participating clinic and proband participant. The investigators will do this by proband participant surveys, as well as initial provider semi-structured interviews. * Proband: Complete Cascade Genetic Testing survey. The survey will also contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. At 6 months, there will be a follow-up survey * Family Member: Complete survey at study entry and at 6 month follow-up